This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet (PODD) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.
BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued
by Zacks Equity Research
Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, View Slashed
by Zacks Equity Research
Zimmer Biomet (ZBH) Q3 sales soft in Americas whereas EMEA and Asia-Pacific register growth at CER.
STERIS (STE) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Solid growth across all three reporting segments drove STERIS' (STE) second-quarter fiscal 2022 revenues.
QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.
Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.
Tandem Diabetes (TNDM) Q3 Earnings Top Estimates, Sales View Up
by Zacks Equity Research
Tandem Diabetes (TNDM) reports better-than-expected revenues for third-quarter 2021 as strong domestic and international pump shipments drive the top line.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results benefit from strong segmental performance.
Change Healthcare (CHNG) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance across Software and Analytics and Network Solutions segments.
Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.
Charles River (CRL) Q3 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
Charles River (CRL) exited the third quarter of 2021 with better-than-expected earnings on strength in the RMS, DSA and Manufacturing Solutions arms driving the top line.
Avanos Medical (AVNS) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) third-quarter 2021 results gains from strength in the Pain Management segment.
Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track
by Zacks Equity Research
An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.
Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.
Fresenius Medical (FMS) Q3 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter earnings benefit from strong performance across the regions, Asia Pacific and Latin America.
PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from strong segmental performance.
CVS Health (CVS) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strength in all three operating segments drove CVS Health's (CVS) revenues in the third quarter of 2021.
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business registered an improvement in revenues during the third quarter on strong contributions from Cologuard volume growth.
Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.
PacBio's (PACB) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.
Catalent (CTLT) Q1 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its first-quarter fiscal 2022 top line.
Henry Schein (HSIC) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the third quarter.
IDEXX (IDXX) Q3 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
IDEXX's (IDXX) Q3 top line rides on strong sales at the CAG and Water businesses.